A Phase 2, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Therapy and Combinations in Pateints with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

August 07, 2018
https://clinicaltrials.gov/ct2/show/NCT03449446
Gastroenterology Hepatology
Principal Investigator: Kimberly A Brown, MD
NASH, nash, nonalcoholic steatohepatitis, fibrosis, f3, f4, cirrhosis, compensated cirrhosis,
Open